<code id='DD3146D15E'></code><style id='DD3146D15E'></style>
    • <acronym id='DD3146D15E'></acronym>
      <center id='DD3146D15E'><center id='DD3146D15E'><tfoot id='DD3146D15E'></tfoot></center><abbr id='DD3146D15E'><dir id='DD3146D15E'><tfoot id='DD3146D15E'></tfoot><noframes id='DD3146D15E'>

    • <optgroup id='DD3146D15E'><strike id='DD3146D15E'><sup id='DD3146D15E'></sup></strike><code id='DD3146D15E'></code></optgroup>
        1. <b id='DD3146D15E'><label id='DD3146D15E'><select id='DD3146D15E'><dt id='DD3146D15E'><span id='DD3146D15E'></span></dt></select></label></b><u id='DD3146D15E'></u>
          <i id='DD3146D15E'><strike id='DD3146D15E'><tt id='DD3146D15E'><pre id='DD3146D15E'></pre></tt></strike></i>

          knowledge

          knowledge

          author:Wikipedia    Page View:55278
          The FDA building -- First Opinion coverage from STAT
          Adobe

          The Food and Drug Administration on Thursday approved the first medicine developed specifically to treat the serious liver disease known as MASH.

          The pill, called Rezdiffra, is made by Madrigal Pharmaceuticals.

          advertisement

          Metabolic dysfunction-associated steatohepatitis, or MASH, is often associated with obesity. The accumulation of fat in the liver causes inflammation, which leads to fibrosis, or liver scarring, and can progress in more advanced stages to cirrhosis, cancer, and the need for a liver transplant.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more
          How to keep neuroscience’s past racism from being its future
          How to keep neuroscience’s past racism from being its future

          De-ShaineMurrayisworkingatthecuttingedgeofneurotechnology.AsapostdoctoralfellowatYale,heisdeveloping

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          Drinking less cuts risk of oral cavity, esophageal cancer: Report

          JEFFPACHOUD/AFPviaGettyImagesReducingoreliminatingalcoholconsumptionreducestheriskofdevelopingoralca